Sara Hurvitz, MD, Spoke on Efficacy of T-DXd in HER2+ Breast Cancer With Brain Metastases
Sara Hurvitz, MD, spoke about ongoing clinical trials in which trastuzumab deruxtecan is being investigated with the use of brain metastases.
Sara Hurvitz, MD, on the Benefit of Second-Line T-DXd in Subgroups of HER2+ Breast Cancer
Sara Hurvitz, MD, spoke which patients would benefit most from fam-trastuzumab deruxtecan and what the next research steps will be.
Sara Hurvitz, MD, Speaks to Improvements in Treatment for HER2+ Breast Cancer
Sara Hurvitz, MD, spoke to the difficulty of treating HER2-positive and advanced HER2-positive breast cancer and how the efficacy of novel agents such as fam-trastuzumab deruxtecan-nxki could make a difference in treating the disease.
Sara Hurvitz, MD, Discusses the Full Approval of Second-Line T-DXd in HER2+ Breast Cancer
Sara Hurvitz, MD, spoke about to recent approval of fam-trastuzumab deruxtecan-nxki in the second-line setting for patients with HER2-positive breast cancer.
2 Clarke Drive Cranbury, NJ 08512